Videos
November 2, 2022

Dr. Brian Dixon: Latest Findings on COVID-19 Boosters for the Immunocompromised

Dr. Brian Dixon: Latest Findings on COVID-19 Boosters for the Immunocompromised

Dr. Brian Dixon explains new findings from a CDC study about the effectiveness of mRNA COVID-19 boosters for immunocompromised adults.

Read the full release

 

Transcript:

Previously, we looked at the primary series and a single booster dose. Here we’re looking at individuals who have more than one booster. This population had access to additional boosters early. So I think what’s new here is that we’re looking at the effectiveness of additional boosters, and there is added protection with the additional booster. I think the other thing that’s new here is that we’re looking at this during the most recent time period (August 2022).   

With the new BA.4, BA.5 strain, individuals with immunocompromised conditions who have received four doses of the vaccine, they have moderate protection against COVID-19, but the protection they have is lower than the general population. One, they need to take extra precautions to prevent from getting sick in the first place, and second, when they are sick, they definitely need to be the ones seeking out these treatments that are in the marketplace to help further prevent severe consequences of COVID-19. 

Related News

Joe Verghese, MD, and Malaz Boustani, MD

$11M NIH grant will support evaluation of Alzheimer’s screening tool in primary care settings

Researchers Led by Albert Einstein College of Medicine, Montefiore Health System, Regenstrief Institute, and IU School of Medicine Will

National study confirms breakthrough COVID cases are less severe than COVID in unvaccinated adults

National study confirms breakthrough COVID cases are less severe than COVID in unvaccinated adults

Hospitalizations, ICU admissions, and hospital deaths lower for those who are vaccinated and boosted Individuals who, despite having been

April Savoy, PhD

Redesigning diabetes technology to detect low blood sugar in older adults with diabetes and Alzheimer’s disease

Regenstrief Institute Research Scientist April Savoy, PhD, a human factors engineer and health services researcher, is developing and testing

illustration of digestive tract with magnifier and stool sample container

New study provides evidence for three-year interval for multi-target stool DNA screening for those at average risk of colon cancer

A scientific study exploring the appropriate interval for colorectal cancer screening via non-invasive multi-target stool DNA testing for individuals